IMP 701

Drug Profile

IMP 701

Alternative Names: ImmunTune IMP701 antagonist antibody - Prima Biomed; IMP701; IMP701 LAG-3 antibody

Latest Information Update: 24 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immutep
  • Developer CoStim Pharmaceuticals; Novartis
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD223 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer
  • Preclinical Infections

Most Recent Events

  • 14 Aug 2015 Phase-I clinical trials in Cancer in USA (Parenteral)
  • 11 Mar 2015 Anti-LAG3 antibodies are covered by patent protection in Canada, China, Europe, Japan, Australia, and USA
  • 17 Dec 2014 Immutep has been acquired by Prima BioMed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top